Health and Me

Supriya Ramesh

Can Potatoes Help Control Obesity? Researchers Say Yes; Know Why, How and More

Credits: Canva

Long seen as the enemy of healthy diets and weight loss plans, the humble potato may be getting a new lease of life, this time, as a key ingredient in fighting <span>obesity</span>. Kolkata researchers have found a way to turn starchy potatoes into a powerful dietary ally. At the Food Technology and Science Institute (<span>FTSI</span>), under TCG CREST, scientists have devised a method to convert potato starch into high-functioning <span>dietary fibre</span>. This fibre is designed to improve <span>gut health</span> and support <span>weight management</span>. 

According to the team, the fibre works as a prebiotic, feeding the gut’s existing good bacteria and helping them thrive, an essential part of maintaining digestion, metabolism, and overall wellness.

Challenging the Potato’s Bad Reputation

Potatoes have long been excluded from weight-loss diets, blamed for belly fat and seen as calorie-dense comfort food. But the development out of FTSI challenges this narrative. The innovation arrives at a time when demand for <span>functional foods</span> is booming in India, with consumers increasingly seeking clean-label, plant-based, and gut-friendly options.

“Much of the core fibre ingredients like inulin, FOS, GOS, and glucans are still imported, mainly from China,” said Prof. Parthasarathi Bhattacharya, Head of FTSI. “That has created concerns around pricing, quality control, and long-term supply.”

India’s Potato Surplus Finds New Purpose

India harvested more than 60 million tonnes of potatoes in the 2024–25 crop year, making it the second-largest producer in the world. A significant portion of this crop ends up in surplus. 

The key lies in a proprietary enzyme developed by the institute. This enzyme can convert starch from potatoes or other carbohydrate-rich crops into dietary fibre. 

“We’re using what India already grows in abundance and giving it a new role,” said Prof. Bhattacharya.

Potatoes as the Future of Functional Snacking

Plans are already underway to integrate this fibre into a range of everyday food products. These include vegan ice creams made from potato “milk”, gummies, protein-rich cones, and high-protein snack bars. Designed to appeal to urban consumers, these products aim to provide indulgent snacking experiences without compromising on health goals.

This trend marks a larger consumer shift, from isolated supplements to functional foods that naturally support wellbeing. Unlike probiotics, which involve introducing live bacteria into the body, <span>prebiotics</span> like <span>potato fibre</span> simply nourish the good microbes already present in the gut, making them easier to incorporate into daily diets.

Beyond potato fibre, the team at FTSI is also working on a range of other innovations such as prebiotic gummies, fungi-based proteins, and preliminary research on postbiotics. The overarching goal remains the same: to create functional food ingredients that are rooted in Indian crops and traditional food practices.

With increasing awareness around health and a growing emphasis on ingredient security, the potato, long vilified in diet culture, could be poised for a comeback. This time, not as a source of guilt, but as a scientifically backed, fibre-rich, gut-friendly food that supports weight control and overall wellness.

Health Conditions A-Z

health

potato fibre

obesity

gut health

prebiotics

dietary fibre

ftsi

weight management

functional foods

indian innovation

starch conversion

Why Are Only Certain People At Risk Of Developing MS? World's First Study Aims To Crack The Code

Who Is Susan Monarez? The New CDC Director Confirmed By The US Senate

What Is 7-OH? All About The 'Legal Compound' Product FDA Urges Restriction On

Health News

Positive Thinking Practice – How Does It Help You?

MIND Diet – Is This A Healthy Diet Or Another Trend?

Yoga Prop Essentials To Improve Your Exercise Session

Should Potatoes Be The Part Of A Healthy Diet?

Best And Worst Foods To Lower Blood Pressure

Low-Impact Cardio Workouts You Should Try

10 Healthy Pasta Salad Dressing For Weight Loss

Breathing Exercise You Should Do To Relieve Stress

Headache vs. Migraine: Difference Explained In 60 Seconds

High Carb Foods That Are Actually Healthy

How Many Times Do You Need To Wash Your Face?

Hypothyroidism Diet – What To Eat And What You Should Avoid

Stretches To Relieve Leg Pain And Numbness After Sitting For Too Long

No-Cook Healthy Meals For Lazy Days At Home

Easy Breakfast Options To Try During Calorie Deficit

How To Stop Muscle Cramps Immediately

Why You Should Go For An Anti-Inflammatory Diet

Foods To Lower Cortisol Levels In Your Body

High-Fiber Dips You Can Make At Home For The Week

Weekend Warrior Exercises To Makeup For Stressful Week

Experiencing Headaches At Word? Natural Remedies To Try

Yoga Poses That Enhance Digestion

Health Benefits of Walking Backwards

No Eggs? Egg-Alternatives You Can Add To Your Diet

Savory And Smart Ways To Add Broccoli To Your Diet

Calorie Burning Habits That Can Help You Shed Extra Pounds

Yoga Poses That Can Help With Bloating

Fiber-Rich Oatmeal Dishes You Can Have For Breakfast

Signs You Must Visit A Doctor For Your Back Pain

Avocado Meal Prep Ideas To Increase Healthy Fat In Your Diet

Arm Exercises You Can Do At Home

Quick-Office Lunches That Can Keep You Full-Longer

How Increased Screen Time Affects Children's Health

Homemade Recipe To Make Protein-Rich Pancakes With Healthy Alternatives

Push-Up Variations You Can Do At Home

Common Mistakes Running Mistakes People Make

Low-Calorie Foods That Keep You Full For Long

Yoga Poses That Help You Get Rid Of Back Pain

Natural Ways To Increase Protein In Your Diet

Managing Excessive Daytime Sleepiness – Tips To Try

Long seen as the enemy of healthy diets and weight loss plans, the humble potato may be getting a new lease of life, this time, as a key ingredient in fighting obesity. Kolkata researchers have found a way to turn starchy potatoes into a powerful dietary ally. At the Food Technology and Science Institute (FTSI), under TCG CREST, scientists have devised a method to convert potato starch into high-functioning dietary fibre. This fibre is designed to improve gut health and support weight management. According to the team, the fibre works as a prebiotic, feeding the gut’s existing good bacteria and helping them thrive, an essential part of maintaining digestion, metabolism, and overall wellness.Challenging the Potato’s Bad ReputationPotatoes have long been excluded from weight-loss diets, blamed for belly fat and seen as calorie-dense comfort food. But the development out of FTSI challenges this narrative. The innovation arrives at a time when demand for functional foods is booming in India, with consumers increasingly seeking clean-label, plant-based, and gut-friendly options.“Much of the core fibre ingredients like inulin, FOS, GOS, and glucans are still imported, mainly from China,” said Prof. Parthasarathi Bhattacharya, Head of FTSI. “That has created concerns around pricing, quality control, and long-term supply.”India’s Potato Surplus Finds New PurposeIndia harvested more than 60 million tonnes of potatoes in the 2024–25 crop year, making it the second-largest producer in the world. A significant portion of this crop ends up in surplus. The key lies in a proprietary enzyme developed by the institute. This enzyme can convert starch from potatoes or other carbohydrate-rich crops into dietary fibre. “We’re using what India already grows in abundance and giving it a new role,” said Prof. Bhattacharya.Potatoes as the Future of Functional SnackingPlans are already underway to integrate this fibre into a range of everyday food products. These include vegan ice creams made from potato “milk”, gummies, protein-rich cones, and high-protein snack bars. Designed to appeal to urban consumers, these products aim to provide indulgent snacking experiences without compromising on health goals.This trend marks a larger consumer shift, from isolated supplements to functional foods that naturally support wellbeing. Unlike probiotics, which involve introducing live bacteria into the body, prebiotics like potato fibre simply nourish the good microbes already present in the gut, making them easier to incorporate into daily diets.Beyond potato fibre, the team at FTSI is also working on a range of other innovations such as prebiotic gummies, fungi-based proteins, and preliminary research on postbiotics. The overarching goal remains the same: to create functional food ingredients that are rooted in Indian crops and traditional food practices.With increasing awareness around health and a growing emphasis on ingredient security, the potato, long vilified in diet culture, could be poised for a comeback. This time, not as a source of guilt, but as a scientifically backed, fibre-rich, gut-friendly food that supports weight control and overall wellness.

can potatoes help control obesity? researchers say yes; know why, how and more

Tanya Dutt

Health & Wellness

What Is The 'Asian Glow'? Is It Just Body's Reaction To Alcohol Or Something More Dangerous?

what is the 'asian glow'? is it just body's reaction to alcohol or something more dangerous?

What Is Metastatic Cancer? How It Spreads, What It Means And Why Chemotherapy Isn’t Always Enough

what is metastatic cancer? how it spreads, what it means and why chemotherapy isn’t always enough

Hepatitis A To E: How Each Virus Affects Your Liver?

hepatitis a to e: how each virus affects your liver?

New Drug Could Stop Alzheimer's In Its Tracks In Just 7 Months

new drug could stop alzheimer's in its tracks in just 7 months

Multiple sclerosis (MS) remains one of the most complex neurological conditions with no known cure. Affecting over 33,000 Australians and 2.8 million people globally, MS continues to baffle scientists and clinicians alike. While environmental factors, genetics, and viral infections have all been linked to MS, no single cause has been confirmed.

Now, a world-first study from the University of South Australia may finally crack part of the code. For the first time, researchers are using a genetic selection method called recall by genotype to understand why some people exposed to the same virus go on to develop MS while others don’t.

At the heart of the study is a long-suspected culprit: the Epstein-Barr virus (EBV), best known for causing glandular fever. More than 90% of the global population gets infected with EBV at some point. Yet only a small fraction develop MS. That’s where the mystery lies- how can one virus lead to a life-altering autoimmune disease in a select few?

Dr. David Stacey, who leads the study, believes the answer may lie in our genes. “It’s like studying the immune system’s blueprint before the disease starts,” he said. The goal is to identify how individuals’ genetic make-up alters their immune response to EBV—and whether that difference tips the scale toward developing MS.

<h2>What Is the ‘Recall by Genotype’ Approach?</h2>

This isn’t just another observational study. The team is using an innovative approach known as recall by genotype, a first in MS research. In simple terms, they’ll analyze the DNA of more than 1,000 participants who have never been diagnosed with MS. These individuals will then be grouped into high-risk and low-risk categories based on their genetic predisposition to MS.

From there, researchers will compare how the immune systems in these two groups respond to EBV exposure.

“By grouping people based on their genetic profile, we expect to find those with a high genetic risk for MS will also show biological differences—even if they don’t have the disease,” explained Dr. Stacey.

This could help pinpoint biomarkers—early warning signs in the body that MS may be developing long before symptoms appear.

<h2>Why This Study Could Be a Game-Changer?</h2>

MS is a central nervous system autoimmune disorder. It causes the immune system to attack the protective sheath covering nerve fibers, resulting in symptoms like fatigue, muscle weakness, poor coordination, vision problems, and cognitive changes. But the progression of the disease is highly unpredictable.

This study, funded by MS Australia’s Incubator Grant program, aims to do more than just explain risk. It could transform the way we approach MS—shifting from reactive care to proactive detection and even prevention.

“If we can identify biological markers before symptoms begin, that opens up new possibilities for early interventions or therapies that could delay or stop disease progression altogether,” said Dr. Stacey.

<h2>Does High Genetic Risk Mean Someone Will Develop MS?</h2>

With genetic research comes another layer of complexity: how much risk information should be shared with participants? Dr. Stacey acknowledges that just because someone has a high genetic risk doesn’t mean they’ll definitely develop MS. That brings up ethical and legal challenges. “If we identify people who are at risk of developing MS, we need to consider how—and whether—to share that information, particularly as it may not yet be clinically actionable,” he said.

Part of the study will address these questions and help lay the groundwork for responsible, patient-centered practices in future genetic research.

While this study is based in Australia, its implications are far-reaching. MS is a leading cause of neurological disability among young adults worldwide. The hope is that by identifying the biological chain of events leading to MS, scientists can develop tools that apply globally—regardless of geography, ethnicity, or background.

According to Rohan Greenland, CEO of MS Australia, “Our mission is to accelerate research and improve outcomes for every person living with MS.” This project exemplifies that vision by targeting the earliest stages of the disease—before symptoms even appear.

If the pilot is successful, it will inform a much larger, more ambitious study. Researchers plan to refine how genetic risk scores are calculated, validate their findings across diverse populations, and develop standardized operating procedures for similar studies worldwide.

This could also inspire studies into other autoimmune conditions like lupus or type 1 diabetes, where viral triggers and genetic susceptibility are believed to intersect.

The world's first “recall by genotype” study in MS research is underway in Australia. By linking genetic risk to immune response against the Epstein-Barr virus, scientists aim to answer a longstanding medical mystery: why only some people develop MS. The findings could pave the way for earlier detection, targeted therapies, and ethical frameworks for sharing genetic information—all with global implications.

multiple sclerosis study

ms genetic risk

epstein barr virus ms

ms australia research

recall by genotype ms

early ms detection

autoimmune disease research

Genetic Disorders

Multiple sclerosis (MS) remains one of the most complex neurological conditions with no known cure. Affecting over 33,000 Australians and 2.8 million people globally, MS continues to baffle scientists and clinicians alike. While environmental factors, genetics, and viral infections have all been linked to MS, no single cause has been confirmed.Now, a world-first study from the University of South Australia may finally crack part of the code. For the first time, researchers are using a genetic selection method called recall by genotype to understand why some people exposed to the same virus go on to develop MS while others don’t.At the heart of the study is a long-suspected culprit: the Epstein-Barr virus (EBV), best known for causing glandular fever. More than 90% of the global population gets infected with EBV at some point. Yet only a small fraction develop MS. That’s where the mystery lies- how can one virus lead to a life-altering autoimmune disease in a select few?Dr. David Stacey, who leads the study, believes the answer may lie in our genes. “It’s like studying the immune system’s blueprint before the disease starts,” he said. The goal is to identify how individuals’ genetic make-up alters their immune response to EBV—and whether that difference tips the scale toward developing MS.What Is the ‘Recall by Genotype’ Approach?This isn’t just another observational study. The team is using an innovative approach known as recall by genotype, a first in MS research. In simple terms, they’ll analyze the DNA of more than 1,000 participants who have never been diagnosed with MS. These individuals will then be grouped into high-risk and low-risk categories based on their genetic predisposition to MS.From there, researchers will compare how the immune systems in these two groups respond to EBV exposure.“By grouping people based on their genetic profile, we expect to find those with a high genetic risk for MS will also show biological differences—even if they don’t have the disease,” explained Dr. Stacey.This could help pinpoint biomarkers—early warning signs in the body that MS may be developing long before symptoms appear.Why This Study Could Be a Game-Changer?MS is a central nervous system autoimmune disorder. It causes the immune system to attack the protective sheath covering nerve fibers, resulting in symptoms like fatigue, muscle weakness, poor coordination, vision problems, and cognitive changes. But the progression of the disease is highly unpredictable.This study, funded by MS Australia’s Incubator Grant program, aims to do more than just explain risk. It could transform the way we approach MS—shifting from reactive care to proactive detection and even prevention.“If we can identify biological markers before symptoms begin, that opens up new possibilities for early interventions or therapies that could delay or stop disease progression altogether,” said Dr. Stacey.Does High Genetic Risk Mean Someone Will Develop MS?With genetic research comes another layer of complexity: how much risk information should be shared with participants? Dr. Stacey acknowledges that just because someone has a high genetic risk doesn’t mean they’ll definitely develop MS. That brings up ethical and legal challenges. “If we identify people who are at risk of developing MS, we need to consider how—and whether—to share that information, particularly as it may not yet be clinically actionable,” he said.Part of the study will address these questions and help lay the groundwork for responsible, patient-centered practices in future genetic research.While this study is based in Australia, its implications are far-reaching. MS is a leading cause of neurological disability among young adults worldwide. The hope is that by identifying the biological chain of events leading to MS, scientists can develop tools that apply globally—regardless of geography, ethnicity, or background.According to Rohan Greenland, CEO of MS Australia, “Our mission is to accelerate research and improve outcomes for every person living with MS.” This project exemplifies that vision by targeting the earliest stages of the disease—before symptoms even appear.If the pilot is successful, it will inform a much larger, more ambitious study. Researchers plan to refine how genetic risk scores are calculated, validate their findings across diverse populations, and develop standardized operating procedures for similar studies worldwide.This could also inspire studies into other autoimmune conditions like lupus or type 1 diabetes, where viral triggers and genetic susceptibility are believed to intersect.The world's first “recall by genotype” study in MS research is underway in Australia. By linking genetic risk to immune response against the Epstein-Barr virus, scientists aim to answer a longstanding medical mystery: why only some people develop MS. The findings could pave the way for earlier detection, targeted therapies, and ethical frameworks for sharing genetic information—all with global implications.

why are only certain people at risk of developing ms? world's first study aims to crack the code

Fitness

RFK Wears Jeans On A Hike And To Gym, Why Is It A Bad Idea?

rfk wears jeans on a hike and to gym, why is it a bad idea?

26 US States Are Witnessing A Spike In The New COVID-19 Variant Cases: How To Keep Your Kids Safe This Summer?

26 us states are witnessing a spike in the new covid-19 variant cases: how to keep your kids safe this summer?

Lyme Disease In US: How Worried Should You Be Of Ticks?

lyme disease in us: how worried should you be of ticks?

what is 7-oh? all about the 'legal compound' product fda urges restriction on

In a closely watched vote, the U.S. Senate confirmed Dr. <span>Susan Monarez</span> as the new Director of the Centers for Disease Control and Prevention (CDC), marking a pivotal moment for an agency under intense political and public scrutiny. The 51-47 confirmation made Monarez the first CDC director to be Senate-confirmed under new legislation passed in 2023. The appointment follows months of leadership vacuum and ideological rifts inside the CDC that have fueled uncertainty in public health circles.

Monarez now steps into a role that has become as much about crisis management and restoring public trust as it is about public health science.

At 50, Dr. Susan Monarez brings a formidable résumé steeped in science, biosecurity, and federal health policy. She holds a PhD in microbiology and immunology from the University of Wisconsin and completed her postdoctoral training at Stanford University. Before joining the CDC, Monarez served as Deputy Director at the Advanced Research Projects Agency for Health (ARPA-H), a government agency known for funding innovative biomedical research.

Her career spans multiple federal agencies including the Department of Homeland Security, the Health Resources and Services Administration, the Office of Science and Technology Policy at the White House, and the Biomedical Advanced Research and Development Authority (BARDA). These roles have given her deep exposure to health innovation, disaster preparedness, and pandemic response policy.

Also Read: <a href="https://www.healthandme.com/health-news/why-are-only-certain-people-at-risk-of-developing-ms-worlds-first-study-aims-to-crack-the-code-article-152372351" data-type="tilCustomLink" target="_blank">Why Are Only Certain People At Risk Of Developing MS? World's First Study Aims To Crack The Code</a>

Monarez has also led the development of national strategies to combat antibiotic resistance, close maternal health gaps, expand telehealth, and ensure the ethical use of health data. Her work has been consistently focused on bridging science and policy to tackle real-world health threats—both globally and domestically.

Monarez’s confirmation ends a stretch of instability at the CDC, which has been operating without a permanent director since early 2025. The agency has faced major staff losses, widespread morale issues, and increasingly vocal political pressure. President Trump’s initial nominee, David Weldon, was withdrawn unexpectedly, and Monarez was named acting director in January before being formally nominated in March.

During her confirmation hearing, Monarez maintained a diplomatic stance affirming her support for vaccines and science-based policy—while skirting direct questions about her relationship with Health Secretary Robert F. Kennedy Jr., whose controversial antivaccine positions have sparked upheaval within the agency. Kennedy has taken bold steps to sideline CDC authority, including bypassing the agency earlier this year to roll back COVID-19 vaccine guidance for pregnant women and children.

That move underscored the new reality Monarez inherits: a CDC whose power and relevance in setting public health policy is being redefined in real-time.

At her Senate hearing, Monarez was clear about her priorities: rebuilding public confidence in the CDC, modernizing outdated data infrastructure, and preparing for future infectious disease threats. These are not minor tasks. The CDC has suffered from a credibility gap over the last several years, exacerbated by mixed messaging during the COVID-19 pandemic, political interference, and what many in the public saw as a lack of transparency.

“She brings decades of distinguished experience in health innovation, disaster preparedness, global health, and biosecurity to CDC,” the agency said in a social media post following the vote. “Dr. Monarez will lead efforts to prevent disease and respond to domestic and global health threats.”

But restoring trust will take more than credentials. The CDC’s internal structure and external messaging need overhauling to match the expectations of a more skeptical and divided public. Monarez is taking over an agency in flux—both scientifically and politically.

<h2>Science and Strategy Behind the Leader</h2>

Monarez’s scientific work reflects a global and future-forward perspective. She has spent her career at the intersection of technology and health policy, especially in biodefense and medical preparedness. At ARPA-H, she helped direct funding toward tools for rapid disease detection, AI-driven health diagnostics, and innovative solutions for behavioral health and maternal care disparities.

She has also been deeply involved in policy development at the national level, helping craft presidential action plans and leading interagency coordination on issues ranging from pandemic preparedness to organ transplantation reform. In previous roles, she worked directly on combating multi-drug-resistant infections and led international collaborations with the EU, Canada, France, and others on biosecurity measures.

This blend of strategic vision and scientific rigor is exactly what public health experts say the CDC needs now—particularly in an era where emerging infectious diseases, misinformation, and technology disruptions often collide.

<h2>What’s Next for the CDC Under Monarez?</h2>

Monarez is stepping into the role amid mounting public health challenges. Vaccine skepticism is on the rise, federal funding for the CDC is set to be slashed under the 2026 budget proposal, and chronic disease burdens continue to grow alongside new threats like drug-resistant bacteria and climate-related health crises.

Her immediate task will be internal stabilization—building back teams, reaffirming scientific values, and reestablishing CDC leadership across state and local public health departments. Externally, she must walk a careful line: maintaining scientific integrity while navigating a politically volatile environment.

Already, her ability to operate in this tension-filled space is under watch. While her academic and professional pedigree earns her respect in science circles, her willingness—or reluctance—to directly challenge political directives from Secretary Kennedy and the White House will define her legacy at the CDC.

Susan Monarez’s confirmation is more than a personnel change; it signals a recalibration of how public health leadership will work in today’s polarized environment. Her track record suggests she understands the complexity and weight of the role.

The real test now is whether she can reassert the CDC’s voice in public health, without becoming another casualty in the ongoing tug-of-war between science and politics.

susan monarez

susan monarez cdc

new cdc director 2025

us senate cdc confirmation

cdc leadership change

dr susan monarez bio

cdc public health head

biden cdc appointment

In a closely watched vote, the U.S. Senate confirmed Dr. Susan Monarez as the new Director of the Centers for Disease Control and Prevention (CDC), marking a pivotal moment for an agency under intense political and public scrutiny. The 51-47 confirmation made Monarez the first CDC director to be Senate-confirmed under new legislation passed in 2023. The appointment follows months of leadership vacuum and ideological rifts inside the CDC that have fueled uncertainty in public health circles.Monarez now steps into a role that has become as much about crisis management and restoring public trust as it is about public health science.Who Is Susan Monarez?At 50, Dr. Susan Monarez brings a formidable résumé steeped in science, biosecurity, and federal health policy. She holds a PhD in microbiology and immunology from the University of Wisconsin and completed her postdoctoral training at Stanford University. Before joining the CDC, Monarez served as Deputy Director at the Advanced Research Projects Agency for Health (ARPA-H), a government agency known for funding innovative biomedical research.Her career spans multiple federal agencies including the Department of Homeland Security, the Health Resources and Services Administration, the Office of Science and Technology Policy at the White House, and the Biomedical Advanced Research and Development Authority (BARDA). These roles have given her deep exposure to health innovation, disaster preparedness, and pandemic response policy.Also Read: Why Are Only Certain People At Risk Of Developing MS? World's First Study Aims To Crack The CodeMonarez has also led the development of national strategies to combat antibiotic resistance, close maternal health gaps, expand telehealth, and ensure the ethical use of health data. Her work has been consistently focused on bridging science and policy to tackle real-world health threats—both globally and domestically.Monarez’s confirmation ends a stretch of instability at the CDC, which has been operating without a permanent director since early 2025. The agency has faced major staff losses, widespread morale issues, and increasingly vocal political pressure. President Trump’s initial nominee, David Weldon, was withdrawn unexpectedly, and Monarez was named acting director in January before being formally nominated in March.    Congratulations to Dr. Susan Monarez, PhD, on her Senate confirmation as the 21st Director of the Centers for Disease Control and Prevention. She brings decades of distinguished experience in health innovation, disaster preparedness, global health, and biosecurity to @CDCgov. Dr.… pic.twitter.com/xG4nsRdFnS&mdash; CDC (@CDCgov) July 29, 2025 ]]>During her confirmation hearing, Monarez maintained a diplomatic stance affirming her support for vaccines and science-based policy—while skirting direct questions about her relationship with Health Secretary Robert F. Kennedy Jr., whose controversial antivaccine positions have sparked upheaval within the agency. Kennedy has taken bold steps to sideline CDC authority, including bypassing the agency earlier this year to roll back COVID-19 vaccine guidance for pregnant women and children.That move underscored the new reality Monarez inherits: a CDC whose power and relevance in setting public health policy is being redefined in real-time.At her Senate hearing, Monarez was clear about her priorities: rebuilding public confidence in the CDC, modernizing outdated data infrastructure, and preparing for future infectious disease threats. These are not minor tasks. The CDC has suffered from a credibility gap over the last several years, exacerbated by mixed messaging during the COVID-19 pandemic, political interference, and what many in the public saw as a lack of transparency.“She brings decades of distinguished experience in health innovation, disaster preparedness, global health, and biosecurity to CDC,” the agency said in a social media post following the vote. “Dr. Monarez will lead efforts to prevent disease and respond to domestic and global health threats.”But restoring trust will take more than credentials. The CDC’s internal structure and external messaging need overhauling to match the expectations of a more skeptical and divided public. Monarez is taking over an agency in flux—both scientifically and politically.Science and Strategy Behind the LeaderMonarez’s scientific work reflects a global and future-forward perspective. She has spent her career at the intersection of technology and health policy, especially in biodefense and medical preparedness. At ARPA-H, she helped direct funding toward tools for rapid disease detection, AI-driven health diagnostics, and innovative solutions for behavioral health and maternal care disparities.She has also been deeply involved in policy development at the national level, helping craft presidential action plans and leading interagency coordination on issues ranging from pandemic preparedness to organ transplantation reform. In previous roles, she worked directly on combating multi-drug-resistant infections and led international collaborations with the EU, Canada, France, and others on biosecurity measures.This blend of strategic vision and scientific rigor is exactly what public health experts say the CDC needs now—particularly in an era where emerging infectious diseases, misinformation, and technology disruptions often collide.What’s Next for the CDC Under Monarez?Monarez is stepping into the role amid mounting public health challenges. Vaccine skepticism is on the rise, federal funding for the CDC is set to be slashed under the 2026 budget proposal, and chronic disease burdens continue to grow alongside new threats like drug-resistant bacteria and climate-related health crises.Her immediate task will be internal stabilization—building back teams, reaffirming scientific values, and reestablishing CDC leadership across state and local public health departments. Externally, she must walk a careful line: maintaining scientific integrity while navigating a politically volatile environment.Already, her ability to operate in this tension-filled space is under watch. While her academic and professional pedigree earns her respect in science circles, her willingness—or reluctance—to directly challenge political directives from Secretary Kennedy and the White House will define her legacy at the CDC.Susan Monarez’s confirmation is more than a personnel change; it signals a recalibration of how public health leadership will work in today’s polarized environment. Her track record suggests she understands the complexity and weight of the role.The real test now is whether she can reassert the CDC’s voice in public health, without becoming another casualty in the ongoing tug-of-war between science and politics.

who is susan monarez? the new cdc director confirmed by the us senate

What Is 7-OH? All About The 'Legal' Product FDA Urges Restriction On

Demand For Weight Loss Injections Now ‘Unsustainable’, Experts Say Most Don’t Qualify

demand for weight loss injections now ‘unsustainable’, experts say most don’t qualify ozempic mounjaro wegovy glp-1 drugs

PTSD In Combat Veterans Could Be Treated With This African Drug - Study Finds

ptsd in combat veterans could be treated with this african drug - study finds

New Sweat-Sensing Wearable Could Help Monitor And Improve Bipolar Disorder Treatment

new sweat-sensing wearable could help monitor and improve bipolar disorder treatment

The U.S. Food and Drug Administration is ringing alarm bells over a potent, opioid-like substance that’s being sold in plain sight—often next to energy drinks, supplements, or flavored vapes. It’s called 7-hydroxymitragynine, or 7-OH, and it’s a concentrated compound derived from the kratom plant.

You’ll find it in gummies, powdered drink mixes, flavored shots, and even ice cream cones. Sold mostly in gas stations, corner stores, and vape shops, these products look benign—but they’re not. According to the FDA, 7-OH has a high potential for abuse and no approved medical use. And now, after a sweeping scientific review, the agency is recommending that 7-OH products be added to the Controlled Substances Act (CSA)—in the same category as heroin and LSD.

Here’s what this means, why it’s happening now, and what consumers should understand before they reach for that "all-natural" stress-relief gummy at the checkout counter.

Kratom is a tropical tree that grows natively in Southeast Asia. Leaves of the tree were used for centuries as a traditional herbal medicine. In the United States, kratom has become popular as an unapproved pain, anxiety treatment, and even opioid withdrawal alternative therapy. Some 1.7 million Americans age 12 and up used kratom in 2021, federal data suggest.

Kratom has two major chemical constituents: mitragynine and 7-hydroxymitragynine (7-OH). The more prevalent and weakly active of these is mitragynine, whereas 7-OH is significantly stronger—directly affecting the brain's mu-opioid receptors, just like morphine or codeine.

Some manufacturers have started isolating and concentrating 7-OH into high doses and selling it separately, completely bypassing the “natural” kratom leaf. These concentrated forms are not regulated, not approved, and far more dangerous than the kratom plant itself.

Unlike prescription opioids, 7-OH products are sold without a prescription or medical oversight, often labeled as supplements or energy enhancers. The FDA has found them being sold in brightly packaged gummies, fruity drinks, tablets, and “wellness shots,” frequently marketed to young people. Many of these items aren’t clearly labeled and may not disclose the amount of 7-OH they contain—or even that it’s included.

In June, the agency sent warning letters to seven companies for illegally selling 7-OH products in violation of federal law. These companies were selling 7-OH in various forms and often making unverified health claims, such as pain relief, anxiety treatment, or arthritis relief—without any scientific evidence to back them up.

According to FDA Commissioner Dr. Marty Makary, “7-OH is an opioid that can be more potent than morphine. We need regulation and public education to prevent another wave of the opioid epidemic.”

The FDA’s latest report includes a clear recommendation: Schedule 7-OH as a controlled substance under the CSA. If accepted, this would make it illegal to sell, distribute, or possess 7-OH without special DEA approval. It would also allow for criminal penalties for unauthorized use.

The Drug Enforcement Administration (DEA) is now reviewing the recommendation. Before any action is finalized, a public comment period will be held, as required by federal law.

The agency made it clear that this action targets only 7-OH, not natural kratom leaf products. However, the distinction is critical, as 7-OH is not lawful in any food or dietary supplement in the United States. It has no FDA-approved uses, and when concentrated, it poses a high risk of abuse, addiction, and overdose.

7-OH mimics the action of opioids in the brain by binding to the same mu-opioid receptors. While users may experience temporary relief from pain or anxiety, the effects can quickly lead to physical dependence, tolerance, and withdrawal symptoms—all hallmarks of substance use disorder (SUD). Some individuals using 7-OH have reported:

<ul><li>Cravings and compulsive use</li><li>Needing higher doses over time to feel the same effects</li><li>Withdrawal symptoms when trying to stop</li><li>Continued use despite serious personal or physical consequences</li></ul>

In rare cases, deaths have been reported in connection with kratom and 7-OH use, though many involved polydrug interactions, making it hard to isolate the role of 7-OH alone. Still, the FDA is not waiting for a full-blown crisis before acting.

While the FDA’s current push is focused on 7-OH, kratom as a whole remains under scrutiny. The agency has not approved any kratom-based drug for treating any condition, and it cannot legally be sold as a dietary supplement or added to food. Products containing kratom are considered “adulterated” under the Food, Drug, and Cosmetic Act.

That’s because, according to FDA analysis, there is insufficient evidence to guarantee that kratom—or its active compounds—can be safely used by consumers. The agency has linked kratom use to liver toxicity, seizures, and interactions with other medications.

The U.S. is still recovering from a devastating opioid crisis, and regulators are keen to avoid repeating history with a new, under-the-radar substance. 7-OH’s legal gray zone, paired with its accessibility and potent opioid-like effects, makes it especially dangerous.

The rise of vape shops and convenience store supplements has allowed these products to proliferate with minimal oversight. In many cases, they’re marketed using the same language as CBD or herbal wellness products—confusing consumers and bypassing safety checks.

“This isn’t just about one compound,” said HHS Secretary Robert F. Kennedy, Jr. “It’s about building a framework that protects youth and families from unregulated, addictive substances dressed up as wellness solutions.”

<h2>What You Should Do as a Consumer?</h2>

The FDA is urging consumers to read labels carefully, avoid products that claim to contain kratom or 7-OH, and report adverse events. The agency is also encouraging healthcare professionals to speak openly with patients about supplement use—especially those purchased outside of pharmacies.

Until thorough research proves safety and effectiveness, the risks of 7-OH far outweigh any perceived benefits. Consumers looking for help with pain, anxiety, or substance use disorders should consult licensed medical professionals—not convenience store counters.

The push to regulate 7-OH underscores a growing challenge in public health: the intersection of wellness marketing, legal loopholes, and addictive substances. As agencies like the FDA and DEA step in, the public’s awareness and skepticism of “natural” supplements needs to catch up. Just because something is sold on a shelf doesn’t mean it’s safe.

7 oh kratom

fda 7 hydroxymitragynine ban

legal opioid supplement

kratom product warning

opioid like energy drinks

7 oh health risks

dea controlled substances act

The U.S. Food and Drug Administration is ringing alarm bells over a potent, opioid-like substance that’s being sold in plain sight—often next to energy drinks, supplements, or flavored vapes. It’s called 7-hydroxymitragynine, or 7-OH, and it’s a concentrated compound derived from the kratom plant.You’ll find it in gummies, powdered drink mixes, flavored shots, and even ice cream cones. Sold mostly in gas stations, corner stores, and vape shops, these products look benign—but they’re not. According to the FDA, 7-OH has a high potential for abuse and no approved medical use. And now, after a sweeping scientific review, the agency is recommending that 7-OH products be added to the Controlled Substances Act (CSA)—in the same category as heroin and LSD.Here’s what this means, why it’s happening now, and what consumers should understand before they reach for that "all-natural" stress-relief gummy at the checkout counter.What Is 7-OH?Kratom is a tropical tree that grows natively in Southeast Asia. Leaves of the tree were used for centuries as a traditional herbal medicine. In the United States, kratom has become popular as an unapproved pain, anxiety treatment, and even opioid withdrawal alternative therapy. Some 1.7 million Americans age 12 and up used kratom in 2021, federal data suggest.Kratom has two major chemical constituents: mitragynine and 7-hydroxymitragynine (7-OH). The more prevalent and weakly active of these is mitragynine, whereas 7-OH is significantly stronger—directly affecting the brain's mu-opioid receptors, just like morphine or codeine.Some manufacturers have started isolating and concentrating 7-OH into high doses and selling it separately, completely bypassing the “natural” kratom leaf. These concentrated forms are not regulated, not approved, and far more dangerous than the kratom plant itself.Why Has FDA Issued A Warning?Unlike prescription opioids, 7-OH products are sold without a prescription or medical oversight, often labeled as supplements or energy enhancers. The FDA has found them being sold in brightly packaged gummies, fruity drinks, tablets, and “wellness shots,” frequently marketed to young people. Many of these items aren’t clearly labeled and may not disclose the amount of 7-OH they contain—or even that it’s included.In June, the agency sent warning letters to seven companies for illegally selling 7-OH products in violation of federal law. These companies were selling 7-OH in various forms and often making unverified health claims, such as pain relief, anxiety treatment, or arthritis relief—without any scientific evidence to back them up.According to FDA Commissioner Dr. Marty Makary, “7-OH is an opioid that can be more potent than morphine. We need regulation and public education to prevent another wave of the opioid epidemic.”The FDA’s latest report includes a clear recommendation: Schedule 7-OH as a controlled substance under the CSA. If accepted, this would make it illegal to sell, distribute, or possess 7-OH without special DEA approval. It would also allow for criminal penalties for unauthorized use.The Drug Enforcement Administration (DEA) is now reviewing the recommendation. Before any action is finalized, a public comment period will be held, as required by federal law.The agency made it clear that this action targets only 7-OH, not natural kratom leaf products. However, the distinction is critical, as 7-OH is not lawful in any food or dietary supplement in the United States. It has no FDA-approved uses, and when concentrated, it poses a high risk of abuse, addiction, and overdose.What Makes 7-OH So Risky?7-OH mimics the action of opioids in the brain by binding to the same mu-opioid receptors. While users may experience temporary relief from pain or anxiety, the effects can quickly lead to physical dependence, tolerance, and withdrawal symptoms—all hallmarks of substance use disorder (SUD). Some individuals using 7-OH have reported:Cravings and compulsive useNeeding higher doses over time to feel the same effectsWithdrawal symptoms when trying to stopContinued use despite serious personal or physical consequencesIn rare cases, deaths have been reported in connection with kratom and 7-OH use, though many involved polydrug interactions, making it hard to isolate the role of 7-OH alone. Still, the FDA is not waiting for a full-blown crisis before acting.Why Kratom Isn’t Safe Either?While the FDA’s current push is focused on 7-OH, kratom as a whole remains under scrutiny. The agency has not approved any kratom-based drug for treating any condition, and it cannot legally be sold as a dietary supplement or added to food. Products containing kratom are considered “adulterated” under the Food, Drug, and Cosmetic Act.That’s because, according to FDA analysis, there is insufficient evidence to guarantee that kratom—or its active compounds—can be safely used by consumers. The agency has linked kratom use to liver toxicity, seizures, and interactions with other medications.The U.S. is still recovering from a devastating opioid crisis, and regulators are keen to avoid repeating history with a new, under-the-radar substance. 7-OH’s legal gray zone, paired with its accessibility and potent opioid-like effects, makes it especially dangerous.The rise of vape shops and convenience store supplements has allowed these products to proliferate with minimal oversight. In many cases, they’re marketed using the same language as CBD or herbal wellness products—confusing consumers and bypassing safety checks.“This isn’t just about one compound,” said HHS Secretary Robert F. Kennedy, Jr. “It’s about building a framework that protects youth and families from unregulated, addictive substances dressed up as wellness solutions.”What You Should Do as a Consumer?The FDA is urging consumers to read labels carefully, avoid products that claim to contain kratom or 7-OH, and report adverse events. The agency is also encouraging healthcare professionals to speak openly with patients about supplement use—especially those purchased outside of pharmacies.Until thorough research proves safety and effectiveness, the risks of 7-OH far outweigh any perceived benefits. Consumers looking for help with pain, anxiety, or substance use disorders should consult licensed medical professionals—not convenience store counters.The push to regulate 7-OH underscores a growing challenge in public health: the intersection of wellness marketing, legal loopholes, and addictive substances. As agencies like the FDA and DEA step in, the public’s awareness and skepticism of “natural” supplements needs to catch up. Just because something is sold on a shelf doesn’t mean it’s safe.

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Can Potatoes Help Control Obesity? Researchers Say Yes; Know Why, How and More

Quick Stories

Why Are Only Certain People At Risk Of Developing MS? World's First Study Aims To Crack The Code

Who Is Susan Monarez? The New CDC Director Confirmed By The US Senate

What Is 7-OH? All About The 'Legal Compound' Product FDA Urges Restriction On

Health Conditions A-Z

Why Are Only Certain People At Risk Of Developing MS? World's First Study Aims To Crack The Code

Who Is Susan Monarez? The New CDC Director Confirmed By The US Senate

What Is 7-OH? All About The 'Legal Compound' Product FDA Urges Restriction On